Consistent CTO Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

215 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-12-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to demonstrate that enhanced vascular healing with the Synergy stent should minimize the risk of late aneurysm formation and potential clinical complications but not at the cost of enhanced efficacy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-acute Coronary occlusIon Treated By Everolimus ELuting Stent

NCT00793221

Coronary Artery Disease Coronary Occlusion Percutaneous Coronary Intervention

COMPLETED PHASE3

CELTIC Bifurcation Study

NCT02232815

Coronary Bifurcations

UNKNOWN

COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials

NCT02723981

Stable Angina Unstable Angina STEMI +2 more

WITHDRAWN PHASE4

Sirolimus-Eluting Stents for Chronic Total Coronary Occlusions

NCT00258596

Coronary Artery Disease Coronary Disease Coronary Stenosis

COMPLETED PHASE3

DISsection RE-entry Evaluation With Absorb Bioresorbable Vascular Scaffolds in CTO.

NCT02936011

Coronary Artery Disease

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Total Occlusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient with chronic total occlusion

Percutaneous coronary intervention

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Percutaneous coronary intervention

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patient \>18 years old
* Females of childbearing potential with a negative pregnancy test
* Presence of Chronic Total Occlusion (CTO) that is known or presumed to be of at least 3 months in duration
* Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent
* Attempt to implant at least one Synergy II stent has been made

Exclusion Criteria

* Acute myocardial infarction with ongoing ST-elevation
* Cardiogenic shock
* Left ventricular ejection fraction \<20%
* Subject has one of the following (as assessed prior to the index procedure):

Other serious medical illness (e.g., cancer, congestive heart failure) with estimated life expectancy of less than 24 months Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.) Planned procedure that may cause non-compliance with the protocol or confound data interpretation

* Subject is treated by dialysis or has a baseline serum creatinine level \>220 μmol/L (2.5 mg/dL)
* Known allergy to to contrast (that cannot be adequately premedicated) and/or the trial stent system or protocol-required concomitant medications (e.g., platinum, platinum-chromium alloy, stainless steel, everolimus or structurally related compounds, polymer or individual components, all P2Y12 inhibitors, or aspirin)
* Subject is participating in another investigational drug or device clinical trial that has not reached its primary endpoint OR subject intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure
* Need for ongoing long-term anticoagulation
* Subject has received an organ transplant or is on a waiting list for an organ transplant
* Subject is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure
* Planned CABG after the index procedure
* Subject previously treated at any time with intravascular brachytherapy
* Subject has a platelet count \<100,000 cells/mm3 or \>700,000 cells/mm3
* Subject has a white blood cell (WBC) count \< 3,000 cells/mm3
* Subject has documented or suspected liver disease, including laboratory evidence of hepatitis
* Subject has a clinically significant bleeding diathesis or coagulopathy or will refuse blood transfusions
* Subject has had a history of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months
* Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding
* Subject has severe symptomatic heart failure (i.e., NYHA class IV)
* Subject with known intention to procreate within 12 months after the index procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure)
* Subject is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No